'YOU ASKED FOR IT' — Congress railed on the maker of EpiPen

Here are a few highlights before we get into the play-by-play: Bresch refused to admit at any point that her company raised the price of the EpiPen to make more money. She also didn't come prepared with information Congress had requested about revenue and the company's patient assistance programs. Bresch couldn't answer those questions off the top of her head either. Mylan's EpiPen4Schools program took a serious beating. Rep. Tammy Duckworth called it a "monopoly" and seemed appalled that schools that entered the program had to sign a noncompete agreement. She was also mad that those schools didn't know that the president of the National Association of State Boards of Education who was lobbying them to join it was actually Bresch's mother. Bresch kept saying that her company saved the US $180 billion in medical expenses, but could never explain how. Throckmorton got slammed because Congress felt the FDA approval process was too onerous, and he couldn't disclose much about any applications for competitors to the EpiPen because of the FDA's rules. Bresch said she didn't plan on raising the price of an EpiPen in 2017, but wouldn't give it a firm no.